🇺🇸 FDA

Company profile · Sponsor

Ipsen

Ipsen Pharma

EEA083C · EMA pharma PARIS, FR
Pipeline
23
Drugs
0
Patents
0

Quick answer

Ipsen (EEA083C) is a pharma company. headquartered in PARIS, FR. listed on EMA. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EEA083C
Exchange EMA
Company type pharma
Headquarters PARIS, FR

Pipeline (23)

Search pipeline →

  1. Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  2. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial

  3. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

  4. Excipients without active substance - Lyophilised powder for solution for injection - Intramuscolar Use

    Ipsen

    Treatment of moderate to severe glabellar lines

    phase 3 small molecule active

    1 trial

  5. KAYFANDA 200 microgram hard capsules, KAYFANDA 400 microgram hard capsules, KAYFANDA 600 microgram hard capsules, KAYFANDA 1 200 microgram hard capsules

    Ipsen

    Alagille Syndrome

    phase 3 small molecule active

    1 trial

  6. elafibranor, Elafibranor Placebo

    Ipsen

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  7. elafibranor, Placebo

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  8. elafibranor, Placebo tablet

    Ipsen

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  9. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  10. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  11. IPN01195, IPN01195

    Ipsen

    Advanced Solid Tumour

    phase 2 small molecule active

    1 trial

  12. IPN01203

    Ipsen

    Advanced Solid Tumor, Metastatic Solid Tumor

    phase 2 small molecule active

    1 trial

  13. IPN10200 placebo, DYSPORT 300 UNITES SPEYWOOD, poudre pour solution injectable, IPN10200

    Ipsen

    Treatment of Moderate to Severe Upper Facial Lines

    phase 2 small molecule active

    1 trial

  14. IPN10200 placebo, Powder for solution for injection, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen

    Upper limb spasticity after stroke or traumatic brain injury

    phase 2 small molecule active

    1 trial

  15. IPN10200, IPN10200 placebo

    Ipsen

    Episodic Migraine Chronic Migraine

    phase 2 small molecule active

    1 trial

  16. IPN60300

    Ipsen

    Advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  17. Placebo capsule

    Ipsen

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  18. Placebo of IPN10200, IPN10200

    Ipsen

    Cervical Dystonia

    phase 2 small molecule active

    1 trial

  19. elafibranor, Placebo of Elafibranor, elafibranor

    Ipsen

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  20. A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants

    Ipsen

    Primary sclerosing cholangitis (PSC)

    phase 1 other active

    1 trial

  21. A study to assess the effect of gemfibrozil, itraconazole and phenytoin on levels of IPN60250 in the blood of healthy adult participant.

    Ipsen

    Not applicable

    phase 1 other active

    1 trial

  22. A study to compare Onivyde manufactured at two different production sites in adult participants with advanced cancer in the pancreas

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  23. BOTOX 200 UNITÉS ALLERGAN, poudre pour solution injectable, DYSPORT 500 UNITES SPEYWOOD, poudre pour solution injectable

    Ipsen

    Upper limb spasticity (ULS) of any aetiology (in US and France) or post- stroke ULS (in Canada)

    approved small molecule active

    1 trial

Frequently asked questions

What is Ipsen?

Ipsen (EEA083C) is a pharma company. headquartered in PARIS, FR. listed on EMA. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Ipsen sponsor?

We track 23 ClinicalTrials.gov-linked programs for Ipsen, including Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung and 22 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Ipsen company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.